Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease
Chunting Zhu, Jie Yang, Yu Sheng, Min Fang · 2026
Read Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease by Chunting Zhu, Jie Yang, Yu Sheng, Min Fang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13222988.txt.
Description
Zhu, Yang, Sheng, and Fang reviewed new drugs and immune therapies for chronic hepatitis B. The virus drives liver inflammation, scarring, and cancer worldwide, and current antivirals suppress it without curing it, because a viral surface protein persists and the immune response stays blunted. The review sorts recent advances into two families: direct antivirals that attack steps in the viral life cycle, and immune approaches meant to restore the body's own control.
The direct-acting group includes entry blockers, gene-silencing RNAs, capsid assembly modulators, and agents that stop surface protein release. Immune options include therapeutic vaccines, receptor agonists, and checkpoint inhibitors. The authors judge combinations that suppress the virus while reviving immunity as the most promising route to a functional cure. They also flag open problems: low cure rates, rebound after stopping, and safety concerns.
Catalog record
| CREATOR | Chunting Zhu, Jie Yang, Yu Sheng, Min Fang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |